People · Operator
Named in public records as an officer, director or promoter · active 2014–2025 · Biotech, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Octave Bioscience Inc | — | Biotech | Series B | $105.8M | $169.3M | 2014 |
| XDx, Inc. | — | Biotechnology | Series B | $44.5M | $879.9M | 2016 |
| Cofactor Genomics, Inc. | — | Biotechnology | Series A | $18.8M | $9.7M | 2021 |
| Bluestem Biosciences, Inc. | — | Biotechnology | Series A | $5.0M | $68.2M | 2022 |
William Hagstrom at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Hagstrom on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Brook Byers | 2 | 13 |
| Fred Cohen | 1 | 12 |
| Michael Goldberg | 1 | 11 |
| Vijay Lathi | 1 | 8 |
| Mark Siegel | 1 | 8 |
| G. Steven Burrill | 1 | 7 |
| Andrea Jackson | 1 | 6 |
| Thomas Hawes | 1 | 6 |
| John Kuelper | 1 | 6 |
| Armen Vidian | 1 | 5 |
| George Scangos | 1 | 4 |
| Mark Weeks | 1 | 4 |
| Michael Pellini | 1 | 4 |
| Ralph Snyderman | 1 | 4 |
| Charles Constanti | 1 | 3 |
| David Levison | 1 | 3 |
| Peter Altman | 1 | 3 |
| Jean Frederic Viret | 1 | 2 |
| Peter Maag | 1 | 2 |
| George Bickerstaff | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.